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Dose-per-Fraction Escalation of Accelerated
Hypofractionated Three-Dimensional Conformal
Radiotherapy in Locally Advanced Non-small Cell Lung
Cancer
Lucyna Kepka, MD, Dobromira Tyc-Szczepaniak, MD, and Krzysztof Bujko, MD
Purpose: To determine the efficacy of accelerated hypofractionated
three-dimensional conformal radiotherapy (3D-CRT) with dose-per-
fraction escalation for treatment of stage III non-small cell lung
cancer (NSCLC).
Patients and Methods: Between 2001 and 2007, 173 patients with
stage III NSCLC were treated using accelerated 3D-CRT and the
simultaneous boost technique. Initially, the total dose of 56.7 Gy
(including 39.9 Gy to the elective area) was delivered over 4 weeks
in fractions of 2.7 Gy (1.9 Gy to the elective area). The dose-per-
fraction escalation study commenced after the outcomes of 70
patients had been evaluated. The dose per fraction was increased
from 2.7 through 2.8 Gy (level 1 escalation) to 2.9 Gy (level 2
escalation); the total dose increased, respectively, from 56.7 Gy
through 58.8 Gy to 60.9 Gy. The dose to the elective area and the
overall treatment time remained unchanged. Fit patients received
two to three courses of chemotherapy before radiotherapy.
Results: The 2- and 3-year overall survival rates were 32 and 19%,
respectively (median survival 17 months). Of the patients, 7% had
grade III acute esophageal toxicity and 6% had grade III or greater
late pulmonary toxicity. Two of the nine patients who received the
level 2 escalation (60.9 Gy) died of pulmonary toxicity. The study
was terminated at a dose of 58.8 Gy and this schema was adopted as
the institutional policy for treatment of stage III NSCLC.
Conclusions: Although dose escalation with accelerated hypofrac-
tionated 3D-CRT was limited, the results and toxicity profiles
obtained using this technique are promising.
Key Words: Non-small cell lung cancer, Accelerated radiotherapy,
Hypofractionation, Simultaneous boost.
(J Thorac Oncol. 2009;4: 853–861)
The current treatment recommendation for stage III inop-erable non-small cell lung cancer (NSCLC) patients is
concurrent radio-chemotherapy (RT-CHT).1,2 This approach
reduces the risk of death at 2 years by 14 and 7% compared,
respectively, with sequential CHT-RT and radiotherapy
alone.3 Nevertheless, this approach is associated with an
elevated incidence (30%) of severe (grade III and higher)
acute esophageal toxicity. It was recently reported that con-
current RT-CHT with conformal techniques results in a 32%
incidence of severe (grade III and higher) pulmonary toxicity
1 year after treatment.4 Its high toxicity renders the concur-
rent approach applicable to few of the general population of
patients with locally advanced NSCLC. Moreover, the cost of
management of treatment-related toxicity is high. For these
reasons, only about 10% of NSCLC patients in Eastern and
Central Europe who are managed with definitive radiotherapy
(RT) receive concurrent treatment.5
The policy of our department on the management of
locally advanced NSCLC has always been to make treatment
convenient and reasonably cheap without compromising its
efficacy for potentially curable patients. We have treated
stage III inoperable patients with accelerated hypofraction-
ated three-dimensional conformal RT (3D-CRT) preceded by
two or three courses of cisplatin-based CHT for fit patients.
We were concerned about the total dose used in the acceler-
ated hypofractionated regimen, as data on this are lacking. To
solve this problem, we performed a study on dose escalation
using the concept of progressive dose-per-fraction escalation
of Mehta et al.,6 which consists of increasing the dose while
keeping treatment time constant. Our rationale was that a
shorter treatment time may overcome the disadvantage of not
administering concurrent treatment and that careful planning
using 3D-CRT tools may facilitate the development of a safe
accelerated hypofractionated regimen. The aim of this study
was to determine the efficacy of accelerated hypofractionated
3D-CRT with an attempt of dose-per fraction escalation for
stage III inoperable NSCLC.
PATIENTS AND METHODS
Patients
Between 2001 and April 2007, 173 patients were
treated according to the accelerated hypofractionated 3D-
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CRT. Patient characteristics are presented in Table 1. All had
stage III NSCLC. The initial staging consisted of clinical
examination, chest and upper abdomen computed tomogra-
phy (CT), lung function tests, bronchoscopy, and brain CT/
magnetic resonance imaging or bone scans if metastases were
suspected. 18FDG-positron emission tomography (PET) was
not available at the time of the study. According to depart-
mental policy, radical RT candidates had to have a Karnofsky
performance status of more than 70, a weight loss over the
previous 6 months of less than 10%, and a forced expiratory
volume (FEV1) of more than 1 liter. Two to three courses of
neoadjuvant cisplatin-based chemotherapy were administered
to fit patients less than 70 years of age.
Radiotherapy and Dose-per-Fraction Escalation
Study
All patients were treated with 4–15 MV photon beams.
The 3D planning was used for all patients. The intensity-
modulated radiation therapy technique was not used. Gross
tumor volume (GTV) was defined as the volume of a macro-
scopic tumor or a pathologic mediastinal/hilar lymph node with
a short-axis diameter of more than 1 cm in a CT image. The
clinical target volume for a boost (CTVboost) was created by
adding a 0.5-cm margin around the primary tumor or by inclu-
sion of the entire volume of the involved lymph node station
(LNS). The planning target volume for a boost (PTVboost)
was defined by adding a 1-cm margin around the CTV boost.
On the rare occasions that the tumor mobility exceeded 1 cm,
a greater margin was used. For lower lobe locations or
patients with respiratory deficiency, the tumor mobility was
assessed at the simulator fluoroscopy and PTVboost margins
were adjusted accordingly. The planning target volume for
limited elective area (PTVelect) encompassed the uninvolved
ipsilateral hilum and mediastinal LNS with the highest prob-
ability of involvement; namely, the 4R, 4L, 7, and for the left
side, the LNS 5 with 1-cm margin. For such defined treatment
volumes, we initially prescribed 56.7 Gy for PTVboost and
39.9 Gy for the elective area. The dose per fraction was 2.7
Gy, including 1.9 Gy for the elective area. Both volumes
were treated during the same fraction using the simultaneous
boost technique. The treatment duration was 26 days. Five
fractions were administered per week, except for the third
week of treatment; during which six fractions were adminis-
tered (the sixth fraction was administered on a Saturday). The
rationale for an additional acceleration of radiotherapy at the
end of the third week was based on the concept of Withers et
al.7 that the repopulation increases between the third and
fourth week of treatment.
The dose-per-fraction escalation study commenced af-
ter the outcome and toxicity of treatment were evaluated for
70 patients. The study was approved by the institutional
ethics committee. The overall treatment time was restricted to
4 weeks, and the dose administered to the elective area
remained unchanged. The dose constraints for critical struc-
tures were unchanged. The dose per fraction was increased in
a stepwise manner from 2.7 Gy per fraction through 2.8 Gy
per fraction (level 1 escalation) to 2.9 Gy per fraction (level
2 escalation) to PTVboost. Thus, the total dose increased from
baseline (56.7 Gy) through 58.8 Gy (level 1 escalation) to
TABLE 1. Characteristics of Patients
Characteristics
Number (%) Unless
Otherwise Stated
Sex
Male 133 (77%)
Female 40 (23%)
Age (yr) Median: 63
(range, 44–82)
70 40 (23%)
70 133 (77%)
Karnofsky performance status
90–100 106 (61%)
70–80 67 (39%)
Weight loss in the previous 6 mo (%)
5 145 (84%)
5 28 (16%)
Smokers
Current 43 (25%)
Former 125 (72%)
Never 5 (3%)
Histology
Squamous 76 (44%)
Adenocarcinoma 23 (13%)
Large cell 2 (1%)
Non-small cell without further specification 42 (42%)
Clinical stage
IIIA 96 (55%)
IIIB 77 (45%)
T stage
T1 4 (2%)
T2 36 (19%)
T3 66 (38%)
T4 67 (39%)
Nodal involvement
N0 10 (6%)
N1 32 (18%)
N2 118 (68%)
N3 13 (8%)
Presence of bulky mediastinal disease (BMD)a
Yes 47 (27%)
No 126 (73%)
Gross tumor volume Median: 111.5 ml
(range, 18–412 ml)
Chemotherapy
Yes 118 (68%)
No 55 (32%)
Chronology of the study
1st period (before dose escalation)—56.7 Gyb 76 (44%)
Dose escalation level 1—58.8 Gy 6 (3%)
Dose escalation level 2—60.9 Gy 9 (5%)
Patients treated after completion of dose
escalation study to dose of 58.8 Gyc
82 (48%)
a Bulky mediastinal disease (BMD) was defined as an initial involvement of at least
three lymph node stations within the mediastinum or an increase in the size of a single
lymph node to at least 3 cm.
b This number includes six patients treated during dose escalation study before
completion of the follow-up for patients from dose escalation level 1; two patients from
this group received dose 54 Gy because of lung dose constraints.
c This number includes three patients with dose of 54 Gy and one who received 56.7
Gy due to lung dose constraints.
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60.9 Gy (level 2 escalation). The biologically effective dose
(BED) for the fractionation schedule (corrected for treatment
duration and proliferation rate) was initially estimated using
following formula6,8: BED nd(1 d/(/)) ln2(T Tk),
where n is the number of fractions; d, dose per fraction; and
T, overall treatment time. The / for lung cancer was
assumed to be 10 and Tk was assumed to be 28 days, the
“kick-off” time for fast proliferation. As T proved to be very
similar to Tk, we subsequently calculated BED without cor-
recting for time, which resulted in values of 72.0, 75.3, and
78.6 Gy for the baseline and two consecutive dose escalation
levels, respectively. From level 1 escalation, the next dose
level was allowed to be started after 3 months of severe
(grade III or higher) toxicity-free follow-up for six patients. If
one case of severe toxicity occurred, the additional six pa-
tients had to be included. If severe toxicity crude rate ex-
ceeded 25% at any level, the study had to be stopped and the
next patients were treated with dose established at the previ-
ous level.
The 3D treatment planning included tissue inhomoge-
neity correction. Dose prescription was done according to
ICRU 50 recommendations. Dose homogeneity had to be
within 95–107% of the prescribed dose for PTVboost. How-
ever, for elective areas, a minimum of 90% of the prescribed
elective dose was allowed. The dose constraints for critical
structures were spinal cord 45 Gy, lung mean dose 20
Gy, lung V20 35%, and heart V40 50%. Although no
special constraints were used for esophagus, special atten-
tion was paid to minimize the maximum doses applied to
this structure.
Chronology of the Study
All patients analyzed in this study were treated strictly
according to the rules described above. All patients were
evaluated prospectively for toxicity using the same scores and
schedule. The same conditions of the follow-up were applied
to 15 patients from the dose escalation study, as to the
remainder. Between 2001 and 2004, the first 70 patients
received 56.7 Gy in 21 fractions. The dose escalation study
(level 1, 58.8 Gy and level 2, 60.9 Gy) included 15 patients
between 2004 and 2005. Simultaneously, additional six pa-
tients were treated with dose 56.7 Gy, when according to the
protocol of the study we had to wait the completion of the
follow-up of the cohort of the dose escalation level 1. From
2005 to April 2007, the dose established at the dose escala-
tion level 1–58.8 Gy was given to 82 patients, as a routine
departmental protocol for stage III patients. As those patients
participate in another prospective study on pulmonary toxic-
ity and pattern of failure, we also have prospective data for
them.
Toxicity Evaluation
Acute pulmonary toxicity was evaluated according to
the Southwest Oncology Group scale9 (grade I, mild symp-
toms for which corticosteroid treatment not required; grade
II, corticosteroid treatment required; grade III, oxygen ther-
apy required; grade IV, assisted ventilation required; and
grade V, toxic death). Acute and late esophageal, heart, and
spinal cord toxicity and late pulmonary toxicity were evalu-
ated according to the Radiation Therapy Oncology Group/
European Organization for Research and Treatment of Can-
cer scale (grades III and IV, symptoms severely affect daily
life; grade V, toxic death). All patients were evaluated for
toxicity weekly during RT, 1 month after completion of
treatment, every 3 months for the next 2 years, and every 6
months thereafter.
Evaluation of Treatment Outcome
Follow-up visits involved clinical examinations and
chest radiographs; chest CT scans were performed 1 and 6
months after RT and thereafter annually or more frequently if
disease progression was suspected. Other examinations were
performed if metastases were suspected. Bronchoscopy and
pulmonary function tests were performed when needed for
clinical purposes. All outcome intervals are expressed rela-
tive to the commencement of RT. Overall survival, local
progression-free survival, distant metastases-free survival,
and isolated nodal failure (INF)-free survival were estimated
using the Kaplan-Meier method. INF was defined as a re-
gional nodal failure of initially uninvolved lymph nodes
without local progression. Local progression was recorded if
a radiologic relapse of the primary tumor or the initially
involved regional lymph nodes occurred after treatment or if
residual disease progressed after RT. When the presence or
absence of local progression was unclear, diagnosis was
confirmed by consecutive examinations. To determine the
significance of prognostic factors for overall survival and
INF-free survival, univariate analysis was carried out using
the log-rank test. Factors affecting overall survival at a
significance level of p  0.10 were included in the multivar-
iate analysis using backward stepwise selection according to
Cox’s regression method. SPSS for Windows software (ver-
sion 14; SPSS, Chicago, IL) was used for statistical analysis.
RESULTS
At the time of the data analysis, 138 patients (80%)
were deceased and 35 patients (20%) were alive. The fol-
low-up interval of living patients ranged from 18 to 84
months (median  32 months). Of the patients who were
censored as alive, two were lost from follow-up, one at 23
months with disease progression, and the other at 64 months
free of disease. Twelve deaths (7%) unrelated to lung cancer
or treatment (without disease progression) occurred between
3 and 49 months of follow-up (median  21 months), of
which nine were related to cardiac and vascular disease, one
to chronic obstructive pulmonary disease complications, and
two to second primary tumors (cervix and larynx).
History of the Dose-per-Fraction Escalation
Study
The first six patients were treated at level 1 escalation
and were followed up every 3 months thereafter, during
which none exhibited RT toxicity of grade III or more. Of the
first group of six patients treated at level 2 escalation, one
with complete response according to chest CT died of pul-
monary toxicity after prolonged grade III toxicity at the
fourth month of follow-up. Consequently, we decided to
include an additional six patients. After inclusion of nine
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patients, we learned that another chronic obstructive pulmo-
nary disease patient from this escalation level had died during
the fourth month of follow-up from acute respiratory distress
syndrome without disease progression. Therefore, we also
attributed this death to treatment toxicity. Because another
patient in this group experienced grade III late pulmonary
toxicity, we stopped accrual for this escalation level and
continued to treat patients at 58.8 Gy, which has become our
routine treatment policy for stage III patients.
Protocol Adherence
Seventy-five patients (43%) received 56.7 Gy in 21
fractions, 84 patients (49%) received 58.8 Gy in 21 fractions,
and 9 patients (5%) received 60.9 Gy in 21 fractions. Five
patients (3%) received the lower dose (54 Gy in 20 fractions),
mainly because of lung dose constraints. Overall treatment
time ranged from 25 to 41 days (median  27 days). Despite
a protocol that required six fractions to be administered
during the third week, a substantial number of patients re-
ceived the sixth fraction during the fourth week because of
logistical constraints. The overall treatment duration was
prolonged for more than 30 days for 31 patients (18%):
technical and logistical reasons in 11 patients, intercurrent
disease in 11 patients, treatment side effects in four patients,
and unknown reasons in five patients. The mean lung dose
ranged from 4 to 28 Gy (median  16 Gy) and the V20 from
8 to 42% (median  28%). The dose constraints for lung
were exceeded in five patients. The maximum spinal cord
dose ranged from 18 to 47 Gy (median  43 Gy).
Toxicity
Esophageal toxicity was mild: 12 patients (7%) ex-
perienced grade III acute toxicity, none experienced grade
III late toxicity, 1 patient (0.5%) experienced grade I late
toxicity, and 3 (2%) experienced grade II late toxicity.
There were three cases of pulmonary toxic deaths (2%)
during the fourth month of follow-up: two died at the
highest dose escalation level as presented previously, and
one died because RT resulted in accelerated progression of
his underlying idiopathic lung fibrosis. The pulmonary
dose constraints were not exceeded in any of these cases.
The characteristics of patients and radiation planning de-
tails of all three cases of pulmonary toxic deaths are
provided in Table 2. Grade I and grade II radiation pneu-
monitis occurred in 21 patients (12%) and 9 patients (5%),
respectively. Severe late pulmonary toxicity (grade III)
occurred in 6 patients (4%). One patient censored at 3
years developed radiation-induced symptomatic pericardi-
tis, which required a few interventions during months
12–20 of follow-up. A diabetic patient aged 62 years
developed paraparesis 6 years after RT. An magnetic
resonance imaging of the thoracic spine revealed vascular
postradiation damage at the level of the irradiated spine.
Grade IV spinal cord toxicity was recorded in this case;
according to the review chart, the maximum dose for the
spinal cord was 44 Gy in 21 fractions. The supposed main
anatomic substrate of the observed damage was located at
the level of the vertebral arteries, where doses varied from
45 to 50 Gy in 21 fractions. We did not observe any other
instance of spinal cord toxicity.
Survival
The 2- and 3-year overall survival rates were 32 and
19%, respectively (Figure 1). The median survival was 17
months. Local progression-free survival and distant metas-
tases-free survival at 2 years was 40 and 53%, respec-
tively. There were 15 cases of INF: the 2-year INF-free
survival rate was 90%. Thirteen of 15 cases of INF
occurred outside the elective fields, nine of which were in
TABLE 2. Characteristics of Three Cases of Pulmonary Toxic Deaths
Patient Characteristics Tumor Characteristics Treatment Plan Details
Pulmonary Complication
Characteristics
Female, 79-yr-old, with chronic
cardiac insufficiency, coronary
and peripheral vascular disease
Adenocarcinoma, T3 N2M0,
multilevel N-invasion;
Right lower lobe location
Radiotherapy alone; Total dose of 60.9 Gy
(level 2 of dose escalation); mean lung
dose—19.7 Gy; lung V20—35%.
Radiation pneumonitis grades
III-IV from months 3 to 4 of
follow-up leading to toxic death
at 4 mo (CR in chest CT).
Female, 51 yr, with chronic
obstructive pulmonary disease
(FEV1 .2 liter; 53% before
treatment)
Squamous carcinoma,
T4N1M0; Right upper lobe
location
Two cycles of induction chemotherapy
(Cisplatin, Vinorelbine); Total dose of
60.9 Gy (level 2 of dose escalation); mean
lung dose—9.0 Gy; lung V20—17%.
Death from Acute Respiratory
Distress Syndrome at fourth
month of follow-up (PR in
chest CT) leading to death.
The underlying condition of
the ARDS was recognized as
aggravation of COPD.
However, the role of
radiotherapy cannot be ruled
out in this context.
Male; 67 yr, with idiopathic
lung fibrosis treated with
immunosuppressive agents for
2 yr and coronary disease
Large cell carcinoma, T2
N2M0; multilevel and
bulky N-invasion; Right
upper lobe location
One cycle of chemotherapy (Cisplatin,
Vinorelbine); The second was not given
due to prolonged and severe hematologic
toxicity; Total dose of 54 Gy (reduced due
to the lung dose constraints); mean lung
dose—19.0 Gy; lung V20—34%.
Death at fourth month (PR in
chest CT) due to aggravation
of underlying idiopathic lung
fibrosis. Radiotherapy was
very likely to be involved in
this aggravation.
CR, complete response; PR, partial response; CT, computed tomography; FEV1, forced expiratory volume in 1 second.
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supraclavicular areas and the upper mediastinum. Never-
theless, in two cases, a dose greater than 40 Gy was
administered because of incidental irradiation. Two INFs
occurred in the elective area and these patients received a
minimum dose of 40 Gy. INF-free survival was adversely
affected (p  0.03) by the presence of bulky mediastinal
disease, which was defined as involvement of more than
three LNSs or an increase in the size of a lymph node in
excess of 3 cm.
Overall survival was not significantly related to sex,
age, smoking status, clinical stage (A versus B), T stage, N
stage, total dose, or chemotherapy. Weight loss greater than
5% (p  0.02), the presence of bulky mediastinal disease
(p  0.03), and a large GTV with a threshold of the median
value of 111 ml (p  0.003) had adverse effects on overall
survival. Lower Karnofsky performance status had also ad-
verse effect on survival but at the p values of 0.07. Relation-
ships between overall survival and weight loss, GTV, bulky
mediastinal disease, chemotherapy, and total dose are shown
in Figures 2 through 6, respectively. In the multivariate
analysis, only weight loss and GTV (with a threshold of the
median value of 111 ml and as a continuous variable) main-
tained significant prognostic significance (p  0.0007 and
p  0.0009, respectively).
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FIGURE 1. Overall survival.
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FIGURE 2. Relationship of weight loss of
more than 5% to overall survival, p  0.02.
Journal of Thoracic Oncology • Volume 4, Number 7, July 2009 Hypofractionated Radiotherapy for NSCLC
Copyright © 2009 by the International Association for the Study of Lung Cancer 857
DISCUSSION
We are unable to prove that our method is equal or
superior to the recommended concurrent RT-CHT method for
lung cancer because our study was not randomized. However,
in terms of survival and toxicity, our mature results for
accelerated hypofractionated RT for locally advanced
NSCLC are similar to those for more aggressive approaches
such as concurrent RT-CHT.1,2
Encouraging results for treatment of lung cancer with
large doses per fraction have been reported by others.10–13
Lester et al.10 studied 135 patients, most of whom had
early-stage NSCLC, exposed to 50–55 Gy in 15–20 fractions,
and showed that the 2-year survival rate was 44%. Slotman et
al.11 reported that the 3-year survival rate of 31 patients with
T1-2N0 tumors who received 48 Gy in 12 fractions was 42%.
Thirion et al.12 escalated the dose up to 72 Gy in 24 fractions
for 25 patients and reported that toxicity was acceptable in the
short term. None of the aforementioned studies used elective
nodal irradiation (ENI), which might have facilitated the use
of a larger dose per fraction. Sun et al.13 studied treatment
with ENI and a concomitant boost for gross disease, as in our
technique. The total dose was 65 Gy in 26 fractions (1.8 Gy
for ENI and 0.7 Gy of boost in the same fraction), which is
equivalent to a lower dose per fraction than that used in our
study and a more protracted overall treatment time than in our
study. Although the toxicity and response rates for the 43
patients were satisfactory, the short follow-up period pre-
cluded conclusions on the utility and safety of the approach.
In this context, only the results of the EORTC 08912
phase I/II14 and EORTC 08972–22973 phase III studies15
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FIGURE 3. Relationship of gross tumor vol-
ume to overall survival, p  0.003. GTV, gross
tumor volume.
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FIGURE 4. Relationship of the presence of bulky
mediastinal disease to overall survival, p  0.03.
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illustrate that for locally advanced NSCLC, the use of ENI
with a concomitant boost for gross disease up to 2.75 Gy per
fraction, even with concurrent low-dose cisplatin (6 mg/m2
daily), to a total dose of 66 Gy is feasible. In this schedule,
after a dose of 55 Gy (including a concomitant delivery of 40
Gy to large elective fields), RT was restricted to boost only.
Acceptable toxicity and overall survival (median  16
months) of a schedule of RT given after neoadjuvant CHT or
concomitantly with low-dose cisplatin treatment has been
demonstrated in a study involving 158 patients.15 Conversely,
the dose escalation using hypofractionation with concurrent
chemotherapy, even with omission of ENI may be challeng-
ing. The RTOG 0117 phase I trial studied a possibility of
giving slightly hypofractionated involved-field radiotherapy
(2.15 Gy per fraction to 75.25 Gy) in concurrent chemother-
apy setting. This study was prematurely closed because of
excessive toxicity.16
We postulate that the shorter overall treatment time was
responsible for the comparatively good results of our RT
schedule, which may be considered suboptimal because of
the absence of concurrent chemotherapy and the relatively
low total dose. Similarly, Cox et al.17 analyzed the RTOG
trials and showed that 3-year survival was worse for patients
in whom treatment was interrupted than for patients in whom
treatment was continuous (17 versus 56%, respectively). The
median decrease in survival was estimated to be 1.6% per day
of treatment delay in excess of 6 weeks. Machtay et al.18 also
reported that prolonged treatment results in significantly
completed censored
Yes
No0 12 24 36 48 60 72 84
Time [months]
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
C
um
ul
at
iv
e 
su
rv
iv
al
FIGURE 5. Relationship of chemotherapy to
overall survival, p  0.25.
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FIGURE 6. Relationship of total dose to
overall survival, p  0.76.
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poorer survival, even in trials in which concurrent CHT-RT is
used. However, the results of randomized trials are inconsis-
tent in respect of the effect of short treatment times on
survival. All published prospective trials have been aimed at
testing the utility of shortening treatment time for NSCLC
using hyperfractionation. The continuous, hyperfractionated,
accelerated radiotherapy trial is the only trial in which a
statistically significant improvement in survival was shown
for hyperfractionated accelerated RT (54 Gy in 36 fractions
over 12 days) compared with the conventional schedule of 60
Gy in 30 fractions over 6 weeks.19 Two other randomized
trials did not show any advantage of acceleration of RT by
hyperfractionation over conventional treatment.20,21 No trials
have been conducted to compare acceleration of RT by
hypofractionation with conventional RT for NSCLC, proba-
bly because of the risk of toxicity. However, we cannot reject
the hypothesis that in lung cancer, some part of the tumor
may have a low / ratio and may be more sensitive to a
larger dose per fraction, in which case, hyperfractionation
would be suboptimal. Modern RT planning techniques may
facilitate delivery of such treatment with minimum toxicity.
In our experience, a 4-week treatment schedule is feasible. Its
outcome seems to be similar to that of more protracted and
expensive strategies. Nevertheless, the relevant caution
should be given to the last statement, because our findings
were not derived from randomized study.
With our technique, we could not escalate the total dose
to more than a BED of 75 Gy. This indicates that dose
escalation with ENI has more limitations than in cases of
involved fields. The use of involved fields only is the most
important feature of dose escalation studies.12,22–24 The role
of ENI in the RT of NSCLC is questioned. Yuan et al.25 have
performed a randomized study comparing use of ENI with
involved fields. Both arms received induction and concurrent
chemotherapy. Patients treated with involved fields received
higher dose and obtained better local control without im-
provement of survival. This trial is up to date the only one
testing the use of ENI in a randomized setting. Even, if this
trial is criticized, because of the different doses used in two
arms, this proves once more, that the omission of ENI
facilitates the dose escalation and the promising results may
be obtained with such an approach. Indications for ENI in
NSCLC are tumor dependent, patient dependent, staging
dependent, and treatment dependent. All these parameters
should be taken into account before a decision about ENI is
taken.26 We have shown in our series of locally advanced
NSCLCs that the rate of INFs outside the radiation field is
quite meaningful. This was related to the high percentage of
the advanced nodal stage, and this parameter was associated
with the risk of INF. Similar findings were observed in our
previous study; namely, that the risk of out-field regional
failure is associated with the presence of bulky mediastinal
disease.27 Most of these failures occurred above the radiation
plane, in the upper mediastinum and supraclavicular areas,
although all LNSs below the upper limit of the aortic arch
(e.g., the lower parts of 3A, 3P, and 6) were not included in
the CTV. This may indicate that for these LNSs, incidental
irradiation may be enough to reduce the risk of nodal failure
but may be insufficient for more cranially located nodal
stations.28 We conclude from this that there are some stage III
NSCLC patients for whom extended ENI is suitable and that
there are other stage III patients for whom dose escalation
with accelerated hypofractionated RT in the absence of ENI
is suitable. There were only nine patients in our high-dose
group and two died of toxicity. However, of the remaining
seven patients, four survived for more than 2 years in com-
plete remission (Figure 6). This might have been a result of
statistical hazard. However, we have some data, indicating
that by an appropriate selection of stage III cases for dose
escalation, we may improve the results for some patients.22–24
We are currently using 18FDG-PET-CT for baseline
staging. Although this method has proven to be useful for
improving staging accuracy for NSCLC patients, in cases of
stage III disease, the sensitivity of PET for detecting the
involvement of mediastinal lymph nodes is limited, and it
underestimates the extent of involved nodes for target defi-
nition.29 Consequently, we continue to use ENI for some
patients. Stage III patients with more advanced nodal status in
the N stage, number, and size of involved lymph nodes
receive the total dose that was established to be safe by the
current study with more extended ENI and inclusion of the
upper mediastinum and supraclavicular areas if they are
clinically fit and lung dose constraints are met. Patients with
involvement of a single mediastinal LNS and all N0 cases
receive RT to the involved fields (with omission of ENI) only
at 60.9 Gy over 4 weeks.
In view of the low toxicity, compliance, and conve-
nience of the accelerated hypofractionated 3D-RT regimen
for patients and medical staff, we conclude that this treatment
may be recommended for locally advanced cases of NSCLC
when concurrent RT-CHT cannot be used.
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